Combinatorial Action of MicroRNAslet-7and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation

Quantification of Therapeutic miRNA Mimics in Whole Blood from Nonhuman Primates

(2014) Kevin Kelnar et al.   ANALYTICAL CHEMISTRY

MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET

(2014) Jian-Ya Zhou et al.   CANCER LETTERS

Aberrant Regulation and Function of MicroRNAs in Cancer

(2014) Brian D. Adams et al.   CURRENT BIOLOGY

In-Depth Analysis Shows Synergy between Erlotinib and miR-34a

(2014) Jane Zhao et al.   PLoS One

MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications

(2013) Carlos Stahlhut et al.   Genome Medicine

miRNA-34 Prevents Cancer Initiation and Progression in a Therapeutically Resistant K-ras and p53-Induced Mouse Model of Lung Adenocarcinoma

(2012) A. L. Kasinski et al.   CANCER RESEARCH

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

miR-34 – a microRNA replacement therapy is headed to the clinic

(2012) Andreas G. Bader   Frontiers in Genetics

Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma

(2011) J Buechner et al.   BRITISH JOURNAL OF CANCER

Genome-wide Characterization ofmiR-34aInduced Changes in Protein and mRNA Expression by a Combined Pulsed SILAC and Microarray Analysis

(2011) Markus Kaller et al.   MOLECULAR & CELLULAR PROTEOMICS

Systemic Delivery of Tumor Suppressor microRNA Mimics Using a Neutral Lipid Emulsion Inhibits Lung Tumors in Mice

(2011) Phong Trang et al.   MOLECULAR THERAPY

Development of a Lung Cancer Therapeutic Based on the Tumor Suppressor MicroRNA-34

(2010) J. F. Wiggins et al.   CANCER RESEARCH

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

(2010) Mallika Singh et al.   NATURE BIOTECHNOLOGY

Beyond Doublet Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Combination of Targeted Agents with First-Line Chemotherapy

(2009) Roy S. Herbst et al.   Clinical Lung Cancer

HuR recruits let-7/RISC to repress c-Myc expression

(2009) H. H. Kim et al.   GENES & DEVELOPMENT

Regression of murine lung tumors by the let-7 microRNA

(2009) P Trang et al.   ONCOGENE

Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

(2008) G. J. Riely et al.   CLINICAL CANCER RESEARCH

Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib

(2008) Vincent A. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Lung Cancer

(2008) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

The MYCN oncogene is a direct target of miR-34a

(2008) J S Wei et al.   ONCOGENE

Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC

(2008) R. S. Herbst et al.   ONCOLOGIST

Selective Blockade of MicroRNA Processing by Lin28

(2008) S. R. Viswanathan et al.   SCIENCE